Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re
Insmed Limited
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"
1 trial -
Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER
Insmed Limited
Pulmonary Hypertension Associated with Interstitial Lung Disease
1 trial -
Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER
Insmed Limited
Pulmonary Hypertension Associated with Interstitial Lung Disease
1 trial -
TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER
Insmed Limited
Pulmonary Arterial Hypertension
1 trial -
BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.
Insmed Limited
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
1 trial -
TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER
Insmed Limited
Pulmonary Arterial Hypertension
1 trial -
The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB
Insmed Limited
Hidradenitis Suppurativa
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources